Skip to content
Screener

Other segment segments

DSA
$20.43M+10.4%
Manufacturing
$5.63M-49.5%

Similar metrics at other companies

National Health Investors logo
NHISHOP — CapEx
$108.29M+7,410%
National Health Investors logo
NHIInvestments — CapEx
$1.12M-98.7%
LKQ logo
LKQEurope — CapEx
$26M-3.7%
Huntington Ingalls Industries logo
HIIIngalls — CapEx
$16M0.0%
LKQ logo
LKQSpecialty — CapEx
$2M-33.3%
IES
IESCCommunications — CapEx
$22.3M+250%

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.56B+70.1%
Enterprise value$15.36B+53.4%
P/S3.1×+1.3×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-6%
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:SegmentExpenditureAdditionToLongLivedAssets.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:21 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001100682-26-000118
Capital Expenditures / Three Months Ended:RMSDSAManufacturingUnallocated CorporateConsolidated
June 27, 2026$4,989$20,433$5,634$49$31,105
June 28, 20253,64018,50011,1611,99735,298
Six Months Ended:
June 27, 2026$16,557$57,942$11,908$606$87,013
June 28, 202510,92653,02128,4402,23594,622
Depreciation and amortization (1)
Three Months Ended:
June 27, 2026$15,733$41,633$7,389$2,535$67,290

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's RMS — capex?
Charles River Laboratories (CRL) reported RMS — capex of $4.99M in Q2 2026.
How has Charles River Laboratories's RMS — capex changed year-over-year?
Charles River Laboratories's RMS — capex increased by 37.1% year-over-year, from $3.64M to $4.99M.
What is the long-term trend for Charles River Laboratories's RMS — capex?
Over 2 years (2023 to 2025), Charles River Laboratories's RMS — capex has grown at a -14.3% compound annual growth rate (CAGR), from $52.82M to $38.84M.
What does RMS — capex mean?
Represents the funds used by the Research Models and Services segment to acquire, upgrade, or maintain physical assets such as facilities, laboratory equipment, and technology infrastructure. These investments are critical for maintaining the segment's operational capacity and long-term competitiveness. It reflects the segment's commitment to growth and asset modernization.

Ask your AI about Charles River Laboratories's rms — capex.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude